Staar Surgical Company · NASDAQ:STAA
Staar Surgical — Investor Presentation (June 2022)
21 slides from Staar Surgical's investor presentation, Jun 7, 2022
Slide 1: STAAR Surgical Investor Presentation
STAAR Surgical Investor Presentation NASDAQ: STAA | June 2022 Exhibit 99.1
Slide 2: Forward Looking Statements
All statements that are not statements of historical fact are forward-looking statements, including statements about any of the following: any financial projections (including sales), plans, strategies, and objectives of management for 2022 or prospects for achieving such plans, expectations for sal
Slide 3: Who Is STAAR Surgical?
Who Is STAAR Surgical? Exclusive manufacturer of proprietary EVO Visian® Family of Implantable Collamer® Lenses (EVO ICL) used worldwide to correct refractive error Executing against a rapidly expanding global Total Addressable Market (TAM) of millions of eyes Achieving industry-leading growth via p
Slide 4: Refractive Error is a Global Epidemic
Refractive Error is a Global Epidemic * Global prevalence of clinically significant astigmatism (>0.75D), Market Scope, 2019. ** BHVI, adapted from Holden et al. 2016 Ophthalmology. *** Fricke, Global Prevalence of Presbyopia and Vision Impairment from Uncorrected Presbyopia, 2018. 04 75-80% of ages
Slide 5: The Existing Myopia Market is Millions of Eyes
The Existing Myopia Market is Millions of Eyes * Market Scope estimates for 2021 published January 2022. One Eye = One Procedure. Procedures rounded to nearest 10,000. R.O.W = Rest of World. Industry reports estimate the global market for refractive procedures will grow from 4 million annually in 20
Slide 6: STAAR's TAM is Tens of Millions of Eyes
STAAR’s TAM is Tens of Millions of Eyes * Company estimates of viable market opportunity. Bilaterally, 35 Million Myopes = 70 Million Lenses and 55 Million Presbyopes = 110 Million Lenses. 06 Myopes Myopes Myopia Eyes Presbyopia Eyes Presbyopes Presbyopes Distance Vision (Nearsightedness) Target Mar
Slide 7: An Evolution in Visual Freedom: STAAR's ICL Technology
An Evolution in Visual Freedom 07 STAAR’S ICL TECHNOLOGY
Slide 8: EVO ICL Technology
EVO ICL Technology 08 Natural Crystalline Lens EVO ICL™ Iris A single-piece foldable phakic intraocular lens (IOL) implanted within the posterior chamber of the eye directly behind the iris and in front of the natural crystalline lens, designed to correct refractive error…
Slide 9: Why EVO ICL? Patients and Surgeons Tell Us…
Why EVO ICL? Patients and Surgeons Tell Us… 09 Bio-Compatible Additive UV Protection Quality of Vision Eco-Friendly Collamer Material Upgradeable Removable Quiet in the Eye Excellent Night Vision No Dry Eye Syndrome No Capital Equipment Investment
Slide 10: Happy ICL Patients
Happy ICL Patients * Packer, The Implantable Collamer Lens with a central port: review of the literature, Clinical Ophthalmology, 2018. 10 2 Million+ ICLs Sold Globally
Slide 11: ICLs Around the World
“@} STAARSURGICAL 7 ra ICL es AROUND THE WORLD vider 9 0 Meo OG $e ae aa oN ae aH ify oN vyetlery, os ~ oo N Sole
Slide 12: China – Increasing Share of #1 Global Market
China – Increasing Share of #1 Global Market 12 Patient roadshows, in-person and virtually on social media such as WeChat, integral to demand cycle China: the first large market to adopt our model of strategic cooperation in 2016 “Hybrid” model, which has 50+ STAAR employees on the ground in country
Slide 13: United States – Executing Playbook as we Launch EVO ICL in #2 Global Market
United States – Executing Playbook as we Launch EVO ICL in #2 Global Market 13 Strategic Imperative Drive U.S. growth by successfully commercializing our market-transforming EVO ICL family of myopia lenses following FDA Approval on March 25, 2022 Build upon foundational work since 2019 to accelerate
Slide 14: Europe – Accelerating a Growth Renaissance
Europe – Accelerating a Growth Renaissance Driving growth via Surgeon Support and Strategic Sales & Marketing Investments Increasing distributor-to-hybrid market conversions with goal of accelerating growth, e.g. France, Italy and Benelux Making sales & marketing investments that include broadening
Slide 15: We're Just Getting Started…
We’re Just Getting Started… * Approximate ICL unit share of 2021 global refractive myopia market. 15 ~ 9% ICL share of global market*
Slide 16: STAAR's Track Record of Strong Financial Performance
16 STAAR’s Track Record of Strong Financial Performance
Slide 17: ICL Unit Growth Significantly Exceeds Refractive Industry
ICL Unit Growth Significantly Exceeds Refractive Industry * Market Scope, January 2019-2022. 17
Slide 18: ICL Unit Growth Drives Industry Leading Net Sales Growth
ICL Unit Growth Drives… Industry Leading Net Sales Growth ~ +25% CAGR * Initial sales outlook provided prior to COVID on January 13, 2020, was for sales mid-point of $177 million or +18% Y/Y Growth for 2020. CAGR of 26% for 2017-2021 and 24% for 2019-2021. 2022 Outlook initially provided January 10,
Slide 19: STAAR's Expanding Margins, EPS and Cash
* 2019 Includes $0.07 GILTI tax benefit. 19 Operating Margin Cash on Balance Sheet - Quarter-End GAAP EPS* Cash from Operations $ Millions STAAR’s Expanding Margins, EPS and Cash
Slide 20: Recent Success and Strong Outlook
Recent Success and Strong Outlook First Quarter 2022 Results Reported May 4, 2022 Focus remains on advancing our strong growth trajectory for EVO ICL lenses Drive surgeon engagement and consumer-patient awareness Net sales outlook of ~ $295 million for fiscal 2022, subject to no unforeseen impact fr
Slide 21: We invite you to visit STAAR’s investor website for clinical papers, examples of global
We invite you to visit STAAR’s investor website for clinical papers, examples of global consumer marketing and much more at investors.staar.com www.staar.com www.discoverevo.com